MX2022012639A - Complejos cristalinos. - Google Patents
Complejos cristalinos.Info
- Publication number
- MX2022012639A MX2022012639A MX2022012639A MX2022012639A MX2022012639A MX 2022012639 A MX2022012639 A MX 2022012639A MX 2022012639 A MX2022012639 A MX 2022012639A MX 2022012639 A MX2022012639 A MX 2022012639A MX 2022012639 A MX2022012639 A MX 2022012639A
- Authority
- MX
- Mexico
- Prior art keywords
- complexes
- crystalline complexes
- crystalline
- sulforaphane
- cyclodextrin
- Prior art date
Links
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 abstract 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 abstract 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 abstract 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 abstract 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005559 sulforaphane Drugs 0.000 abstract 1
- 235000015487 sulforaphane Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/16—Isothiocyanates
- C07C331/18—Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms
- C07C331/20—Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a complejos cristalinos de sulforafano y alfa-ciclodextrina; composiciones farmacéuticas que comprenden los complejos; métodos para su fabricación; y el uso de dichos complejos como medicamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005238.7A GB202005238D0 (en) | 2020-04-08 | 2020-04-08 | Crystalline complexes |
| PCT/GB2021/050861 WO2021205171A1 (en) | 2020-04-08 | 2021-04-08 | Crystalline complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012639A true MX2022012639A (es) | 2023-01-05 |
Family
ID=70768898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012639A MX2022012639A (es) | 2020-04-08 | 2021-04-08 | Complejos cristalinos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230322666A1 (es) |
| EP (1) | EP4132654A1 (es) |
| JP (1) | JP2023521984A (es) |
| KR (1) | KR20230017173A (es) |
| CN (1) | CN115515684A (es) |
| AU (1) | AU2021253214A1 (es) |
| BR (1) | BR112022020216A2 (es) |
| CA (1) | CA3179780A1 (es) |
| CL (1) | CL2022002752A1 (es) |
| GB (1) | GB202005238D0 (es) |
| IL (1) | IL297056A (es) |
| MX (1) | MX2022012639A (es) |
| WO (1) | WO2021205171A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3354267T (lt) * | 2007-01-23 | 2019-09-25 | Pharmagra Labs, Inc. | Stabilizuotas sulforafanas |
| CN104703628B (zh) * | 2012-06-01 | 2017-09-08 | 法玛格拉实验室公司 | 合成萝卜硫烷的方法 |
| US9603828B2 (en) * | 2012-06-01 | 2017-03-28 | Pharmagra Labs, Inc. | Sulforaphane isolation and purification |
-
2020
- 2020-04-08 GB GBGB2005238.7A patent/GB202005238D0/en not_active Ceased
-
2021
- 2021-04-08 WO PCT/GB2021/050861 patent/WO2021205171A1/en unknown
- 2021-04-08 MX MX2022012639A patent/MX2022012639A/es unknown
- 2021-04-08 IL IL297056A patent/IL297056A/en unknown
- 2021-04-08 CN CN202180027413.7A patent/CN115515684A/zh active Pending
- 2021-04-08 BR BR112022020216A patent/BR112022020216A2/pt unknown
- 2021-04-08 JP JP2022561646A patent/JP2023521984A/ja active Pending
- 2021-04-08 EP EP21719218.6A patent/EP4132654A1/en active Pending
- 2021-04-08 AU AU2021253214A patent/AU2021253214A1/en active Pending
- 2021-04-08 KR KR1020227039039A patent/KR20230017173A/ko active Search and Examination
- 2021-04-08 US US17/995,617 patent/US20230322666A1/en active Pending
- 2021-04-08 CA CA3179780A patent/CA3179780A1/en active Pending
-
2022
- 2022-10-06 CL CL2022002752A patent/CL2022002752A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022002752A1 (es) | 2023-04-14 |
| AU2021253214A1 (en) | 2022-11-03 |
| KR20230017173A (ko) | 2023-02-03 |
| EP4132654A1 (en) | 2023-02-15 |
| BR112022020216A2 (pt) | 2022-11-22 |
| IL297056A (en) | 2022-12-01 |
| CN115515684A (zh) | 2022-12-23 |
| JP2023521984A (ja) | 2023-05-26 |
| US20230322666A1 (en) | 2023-10-12 |
| GB202005238D0 (en) | 2020-05-20 |
| CA3179780A1 (en) | 2021-10-14 |
| WO2021205171A1 (en) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019012676A (es) | Derivados de 2-aminoquinolina. | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2012012837A (es) | Composiciones farmaceuticas y metodos para su elaboracion. | |
| MX2018015709A (es) | Derivados de azabencimidazol como inhibidores de pi3k beta. | |
| EA201992116A1 (ru) | Фармацевтические составы флороглюцинола и триметилфлороглюцинола | |
| MX2018011627A (es) | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles. | |
| MX2023009205A (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. | |
| MX2015011245A (es) | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. | |
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| MX2020005944A (es) | Analogos espirobiciclicos novedosos. | |
| PH12017500810A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| MX2021006969A (es) | Ligante peptidico. | |
| PH12020550616A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| ZA202109193B (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| MX2018004304A (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
| MX2023002117A (es) | Forma amorfa de un inhibidor de malt1 y formulaciones de este. | |
| MX2023006677A (es) | Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme). | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| MX2022012639A (es) | Complejos cristalinos. | |
| PH12019501820A1 (en) | Pharmaceutical compositions for combination therapy | |
| IN2014DN03010A (es) | ||
| MX2022002185A (es) | Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso. | |
| EP4342542A3 (en) | Combination of regorafenib and nivolumab for treating cancer |